Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): Results of a multicentric Italian observational study.

Abstract

e13053Background: Most of HR+ MBC pts receive both hormonal therapy (HT) and chemotherapy (CT) during the course of their disease. According to international guidelines, HT should be preferred over CT in the first-line setting, restricting CT only to pts not responsive to HT or at risk of visceral crisis. Observational studies indicate that nearly 50% of this pts receive CT as first - line treatment. We aimed to evaluate if this behaviour does change in recent years. Methods: All consecutive MBC pts receiving a first-line treatment at 13 centers of GIM group (Gruppo Italiano Mammella) from 2000 to 2017 were registered. For the purpose of this analysis, we selected only HR+ MBC. The choice between first - line HT or CT was performed by the treating physician on the basis of pts and disease characteristics. The type of first line treatment (HT or CT) was analyzed according to four different cohorts: 2000 - 2005; 2006 - 2010; 2011 - 2013; 2014 - 2017. Results: 1709 pts with MBC were included in the GIM regis...